Rundo Pharmaceutical Research Announces RMB 100 Million Series C Financing to Deepen Services in Drug Development Market

In May 2019, VCBeat learned that Rundo Research & Development (Shanghai) Co., Ltd. (“Rundo Pharma”) had recently completed a C-round financing of hundreds of millions of RMB, with exclusive investment from RHC. Previously, Rundo Pharma had also received investments from renowned institutions such as Shenzhen Capital Group and Honghui Capital.

Rundo Pharma, established in 2004 and headquartered in Shanghai, specializes in providing clinical research outsourcing services to pharmaceutical and biotechnology companies both in China and abroad. Over the past 15 years, Rundo Pharma has grown into one of the few domestic CROs capable of delivering one-stop clinical trial services from Phase I to Phase IV, positioning itself as a leading enterprise among China’s local CROs. Since its inception, the company has successfully completed nearly 700 clinical trial projects with high quality, including more than 20 international multi-center trials. Its service capabilities have earned the strong trust of numerous domestic and international pharmaceutical clients, such as Pfizer, Novartis, and Otsuka, as well as widespread recognition from researchers.

Following the completion of this round of financing, Rundo Pharma will accelerate its expansion into international markets by establishing a U.S. subsidiary, speeding up business development in Japan, and significantly enhancing its data statistical analysis capabilities. While consolidating relationships with multinational pharmaceutical clients, the company will prioritize domestic innovative drug projects as a strategic focus. It will expedite the construction of Phase I clinical trial centers for healthy volunteers and oncology patients, helping clients optimize Phase I clinical trial protocols and improve R&D efficiency through more comprehensive services. Meanwhile, Rundo Pharma will further refine its Clinical Trial Management System (CTMS) to achieve more efficient and standardized workflows, aiming to substantially boost per capita productivity and corporate profitability.

Mr. Xu Liedong, President and CEO of Rundo Pharma, stated, “With the vigorous growth and increasing maturity of China’s pharmaceutical R&D industry, market demand for clinical CROs with professional service capabilities continues to rise. As one of the industry leaders, Rundo Pharma aims to further strengthen its scientific team, enhance delivery capabilities, and particularly increase investment in clinical trial management systems. We are committed to building an integrated, digital, and standardized clinical development platform to consistently provide customers with high-quality, efficient, and first-class services.”

Mr. Huang Shengxuan, General Manager of RHC, stated, “RHC is delighted to enter into a strategic partnership with Rundo Pharma. We are optimistic about the trend-driven opportunities in the clinical CRO industry. China’s encouragement of innovative drug development is driving the sustained and rapid growth of the CRO sector. Meanwhile, following China’s accession to the ICH, international multi-center clinical trials have created more outsourcing opportunities for domestic CRO companies from global pharmaceutical firms. Rundo Pharma not only possesses extensive operational experience in China but also integrates advanced operational concepts from leading international CROs. The company is rapidly iterating and upgrading its service quality, operational efficiency, and management capabilities. Aligned with our investment strategy of empowering healthcare through insurance, we aim to foster synergy between the company and industrial resources such as Sunshine Insurance Group and Sunshine Union Hospital, becoming a long-term partner that supports Rundo Pharma’s continuous development.”

RHC is among the first insurance-affiliated private equity fund management companies approved by the China Insurance Regulatory Commission (CIRC). Its business segments include equity investment, real estate investment, and wealth management. With assets under management totaling RMB 18 billion, RHC has invested in numerous leading enterprises across the healthcare, technology, and financial sectors, including Mindray Medical, Ruipeng Pet Healthcare, Bikang Pharmaceuticals, Chaoju Eye Care, 360, JD Digits, Didi, Full Truck Alliance, Shiqiao, SenseTime, and QingCloud.